



Announcement Regarding the Transfer of Sales from Kyowa Kirin to LEO Pharma Following the Termination of the Distribution and Co-Promotion Agreement for the Psoriasis Vulgaris Treatment "Dovobet[®] Ointment, Gel, and Foam" in Japan

Tokyo, Japan, November 1, 2024 — LEO Pharma K.K. (Head Office: Tokyo, Representative Director: Kris Sisneros, "LEO Pharma") and Kyowa Kirin Co., Ltd. (Head Office: Tokyo, TSE:4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin") announce that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment "Dovobet[®] Ointment, Gel, and Foam" (generic name: calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024.

Kyowa Kirin, LEO Pharma, and its parent company LEO Pharma A/S entered into a distribution and co-promotion agreement for Dovobet[®] in December 2013. Under this agreement, LEO Pharma has been responsible for product production and sales, while Kyowa Kirin has handled sales and provided medical information to healthcare professionals via its medical representatives. Both marketing activities have been jointly conducted by LEO Pharma and Kyowa Kirin.

With the termination of this agreement, Kyowa Kirin's sales of Dovobet[®] Ointment, Gel, and Foam will be suspended on December 31, 2024. Starting January 1, 2025, LEO Pharma will continue to manage the production, sales, and marketing, and additionally to start providing medical information regarding for Dovobet[®] Ointment, Gel, and Foam to healthcare professionals via its medical representatives.

About Dovobet[®]

Dovobet[®], developed by LEO Pharma A/S, the parent company of LEO Pharma, has been widely used in many markets* since its initial launch of the ointment formulation in Denmark in 2001 and the gel formulation in the United States in 2008. In Japan, Dovobet[®] Ointment has been available since September 2014, Dovobet[®] Gel since June 2018, and Dovobet[®] Foam since June 2021.

*The number of available markets:

Dovobet [®] Foam	41	Dovobet [®] Gel	58	Dovobet [®] Ointment	56
---------------------------	----	--------------------------	----	-------------------------------	----

About LEO Pharma

LEO Pharma Co., Ltd. was established in June 2010 as a 100% owned Japan subsidiary of LEO Pharma A/S in Denmark. As a specialty pharma specializing in the dermatology field, we are developing our



business activities to establish a solid position in Japan. For more information, please visit <http://www.leo-pharma.jp/>

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hematology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: <https://www.kyowakirin.com>.